Search
News & Events
New eczema storybook to promote healthy skinA children’s book – written by community, for community – has been launched in Western Australia’s south-west to help children and families understand more about one of the most common inflammatory skin conditions in children.
News & Events
Australia Day Honours for researchers and esteemed ElderFour outstanding members of The Kids Research Institute Australia family – three researchers and an Aboriginal Elder co-researcher – have been named in the Australia Day Honours List for their outstanding service to research and the community.
News & Events
OPINION: Fiona Stanley and Dan McAullay: Close the Gap focus ignores positivesThis opinion article was originally published in the West Australian on July 20, 2023.
News & Events
Wet cough prevalence among Aboriginal children ‘concerningly high’The Kids Research Institute Australia and Perth Children’s Hospital clinician-researchers have found more than one in ten children across four remote Kimberley communities have protracted bacterial bronchitis.
The Aboriginal Health and Wellbeing Team follows an holistic definition of Aboriginal Health which means that health is not just the physical wellbeing of an individual but includes the social, emotional and cultural wellbeing of the whole community.
The fifth Big Elders meeting/gathering was held on the Wednesday, 28th of February 2024 at Burswood on Swan.
People
Associate Professor Glenn PearsonDirector of First Nations Strategy and Leadership; Head, First Nations Health and Equity Research
Research
Interchangeability, immunogenicity and safety of a combined 10-valent pneumococcal Haemophilus influenzae protein D conjugate vaccine (Synflorix) and 13-valent-PCV (Prevenar13) schedule at 1-2-4-6 months: PREVIX_COMBO, a 3-arm randomised controlled trialAboriginal children living in remote communities are at high risk of early and persistent otitis media. Streptococcus pneumoniae and non-typeable Haemophilus influenzae (NTHi) are primary pathogens. Vaccines with potential to prevent early OM have not been evaluated in this population. We compared immunogenicity (ELISA and opsonophagocytic activity) of a combination of Synflorix™ (PHiD-CV10, 10 serotypes and protein D of NTHi) and Prevenar13™ (PCV13, 10 serotypes plus 3, 6A, and 19A), with recommended schedules.